Cargando…

KRAS Mutations in Squamous Cell Carcinomas of the Lung

KRAS is one of the most commonly mutated oncogenes in cancer, enabling tumor proliferation and maintenance. After various approaches to target KRAS have failed over the past decades, the first specific inhibitor of the p.G12C mutation of KRAS was recently approved by the FDA after showing promising...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acker, Fabian, Stratmann, Jan, Aspacher, Lukas, Nguyen, Ngoc Thien Thu, Wagner, Sebastian, Serve, Hubert, Wild, Peter J., Sebastian, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714661/ https://www.ncbi.nlm.nih.gov/pubmed/34976827 http://dx.doi.org/10.3389/fonc.2021.788084

Ejemplares similares

Obesity is associated with an impaired survival in lymphoma patients undergoing autologous stem cell transplantation
por: Scheich, Sebastian, et al.
Publicado: (2019)

Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
por: Stratmann, Jan A., et al.
Publicado: (2022)

Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
por: Althoff, Friederike C., et al.
Publicado: (2023)

Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
por: Xiu, Weigang, et al.
Publicado: (2021)

Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations
por: Koschade, Sebastian E., et al.
Publicado: (2022)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Discovery, Significance, and Utility of JAK2 Mutation in Squamous Cell Carcinoma of the Lung
por: Hundal, Jasmin, et al.
Publicado: (2022)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Somatic mutation detection and KRAS amplification in testicular germ cell tumors
por: Cabral, Eduardo R. M., et al.
Publicado: (2023)

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
por: Wang, Jianlei, et al.
Publicado: (2022)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis
por: Cai, Peiling, et al.
Publicado: (2023)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
por: Kordiak, Jacek, et al.
Publicado: (2018)

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
por: Yang, Haitang, et al.
Publicado: (2019)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
por: Xiang, Luochengling, et al.
Publicado: (2020)

EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
por: Jin, Rui, et al.
Publicado: (2021)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
por: Boch, Christian, et al.
Publicado: (2013)

Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived From Gprc5a-Deficient Murine Lung Adenocarcinoma With Somatic Kras Mutations
por: Daouk, Reem, et al.
Publicado: (2019)

Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD
por: Stasik, Sebastian, et al.
Publicado: (2022)

Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations
por: Kalari, Krishna R., et al.
Publicado: (2012)

Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience
por: Koschade, Sebastian E., et al.
Publicado: (2023)

Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2021)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort
por: Mangalaparthi, Kiran K., et al.
Publicado: (2020)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Heterogeneous pattern of gene expression driven by TTN mutation is involved in the construction of a prognosis model of lung squamous cell carcinoma
por: Liu, Zhao, et al.
Publicado: (2023)

Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2021)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer
por: Tran, Le Son, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_84peskd93rli0f8rjesgivac4j